United Health Products Announces Distributor to the Veterinarian Market

Colts Neck, NJ – March 21, 2012 – United Health Products, Inc.(OTCQB:UEEC) which develops and markets products and technologies in the healthcare sector, today announced it has executed a Distribution Agreement with BioVentive Inc. for the exclusive rights to distribute its Hemostyp™ product line into the veterinarian market both domestically and internationally.

In the United States, the American Pet Products Association estimates that 62% of all households own a pet (i.e., dog, cat, horse, bird, fish or reptile) which equates to 72.9 million homes. The American Veterinary Medical Association estimates that the number of procedures performed on animals, whether due to injury or health related issues exceeds 10 million, annually. Hemostyp gauze technology is designed to absorb exudate/drainage from superficial wounds and assists the veterinarian in expediting the delivery of service.

Dr. Phillip Forman, UHP's CEO, said, "I am very excited about our agreement with BioVentive to promote our products in the veterinarian market. The absorption quality inherent in our Hemostyp™ products can now be implemented in numerous fashions in the treatment of pets including tooth extractions and superficial trauma." 

"Hemostyp™ will be a key product line to help position our company to offer advanced life saving technology, at the right price, in order to achieve significant market share in the worldwide veterinarian market over the next 12 months," says Brett Nauta, President of BioVentive, Inc. 

About BioVentive, Inc.
BioVentive is a private company based in California that sells and distributes products to the medical and veterinary markets. BioVentive markets products that consist of enhanced infection prevention solutions, stem cell therapies and collection, and specialized wound care products and solutions. Its over 100 member sales force includes specialists to service the genetic therapy and wound care management in the veterinarian market. The company works both as a direct re-seller and channel partner of major worldwide distributors. 

About United Health Products, Inc.
United Health Products, Inc. (UEEC) develops, manufactures, and markets a patent pending hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp™, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on ramping up sales in its current markets as well as identifying new markets and applications for its products and technologies. For more information on United Health Products, Inc. please visit: www.unitedhealthproductsinc.com.

Safe Harbor Statement 
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements 

Contact:
United Health Products, Inc.
Dr. Phillip Forman, 732-239-3444
CEO